MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.radonc.2026.111791

Медицинская библиотека · Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026

LINACS: an ESTRO/OligoCare living systematic review of the safety of concurrent stereotactic radiotherapy and novel systemic therapies (version 1).

Sundahl Nora, Looman Esmée Lauren, Ollivier Luc, Bagnalasta Matteo, Ost Piet, Guckenberger Matthias, Ryckman Jeffrey, Culbert Matthew, Bekkering Geertruida, Reichl Sabrina

СтатьяОбзорПеревод в очереди

Аннотация

BACKGROUND

New safety evidence on the combination of stereotactic radiotherapy (SRT) and novel systemic therapies is emerging at an accelerating pace. Conventional systematic reviews quickly become outdated, limiting their value for clinical decision-making.

AIM: We established the first living systematic review on this topic, providing continuously updated evidence through biannual literature surveillance and immediate online dissemination (https://linacs.net). This dynamic approach delivers current estimates of high-grade adverse events (AEs) to support evidence-based practice.

METHODS

Search terms (including newly approved drugs), searches and analyses are updated biannually. PubMed is searched (from January 1, 2000) for studies reporting original data on patients receiving SRT within 30 days of novel systemic therapy. Current search: April 2, 2026. Studies with a high risk of bias are excluded as per standard methods. The primary outcomes are pooled estimates of grade ≥ 3 overall treatment-related AEs (OAE) and RT-related AEs (RTAE). PROSPERO registration: CRD42024559453.

RESULTS

191 studies comprising 7,694 patients were included-nearly tripling the evidence base of the last published conventional systematic review in 2023 and covering 14 additional drug groups (combinations). EGFR-targeting TKIs showed no clear evidence of excess AEs. Substantial RTAE rates were observed for BRAF/MEK inhibitors and trastuzumab-emtansine. Although anti-PD-(L)1 therapies and multi-target TKIs had low overall RTAE rates, both were associated with high OAEs following liver SRT.

CONCLUSIONS

Given the exponential growth of evidence, this living systematic review offers a new model for delivering current clinical guidance by collecting and reanalyzing all available data biannually and making it immediately accessible online (https://linacs.net).

Для цитирования: Sundahl Nora, Looman Esmée Lauren, Ollivier Luc, Bagnalasta Matteo, Ost Piet, Guckenberger Matthias, Ryckman Jeffrey, Culbert Matthew, Bekkering Geertruida, Reichl Sabrina. LINACS: an ESTRO/OligoCare living systematic review of the safety of concurrent stereotactic radiotherapy and novel systemic therapies (version 1).. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2026. DOI: 10.1016/j.radonc.2026.111791.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.